Loader

Pathways

PathWhiz ID Pathway Meta Data

PW147059

Pw147059 View Pathway
metabolic

Trolamine Drug Metabolism Pathway

Homo sapiens

PW146119

Pw146119 View Pathway
drug action

Trolamine polypeptide oleate condensate Drug Metabolism Action Pathway

Homo sapiens

PW127675

Pw127675 View Pathway
drug action

Trolamine salicylate Action Pathway

Homo sapiens
Trolamine salicylate is a nonsteroidal anti-inflammatory agent (NSAID) used for the temporary relief of some minor aches and pains of the muscles and joints associated with backache, lumbago, strains, bruises, sprains, and arthritic or rheumatic pain, pain of tendons and ligaments. This drug is used as a topical analgesic. It targets the prostaglandin G/H synthase-1 (COX-1) and prostaglandin G/H synthase-2 (COX-2) in the cyclooxygenase pathway. The cyclooxygenase pathway begins in the cytosol with phospholipids being converted into arachidonic acid by the action of phospholipase A2. The rest of the pathway occurs on the endoplasmic reticulum membrane, where prostaglandin G/H synthase 1 & 2 convert arachidonic acid into prostaglandin H2. Prostaglandin H2 can either be converted into thromboxane A2 via thromboxane A synthase, prostacyclin/prostaglandin I2 via prostacyclin synthase, or prostaglandin E2 via prostaglandin E synthase. COX-2 is an inducible enzyme, and during inflammation, it is responsible for prostaglandin synthesis. It leads to the formation of prostaglandin E2 which is responsible for contributing to the inflammatory response by activating immune cells and for increasing pain sensation by acting on pain fibers. Trolamine salicylate inhibits the action of COX-1 and COX-2 on the endoplasmic reticulum membrane. This reduces the formation of prostaglandin H2 and therefore, prostaglandin E2 (PGE2). The low concentration of prostaglandin E2 attenuates the effect it has on stimulating immune cells and pain fibers, consequently reducing inflammation and pain.

PW132260

Pw132260 View Pathway
metabolic

Trolamine salicylate Drug Metabolism

Homo sapiens
Trolamine salicylate is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Trolamine salicylate passes through the liver and is then excreted from the body mainly through the kidney.

PW146219

Pw146219 View Pathway
drug action

Trolamine salicylate Drug Metabolism Action Pathway

Homo sapiens

PW124332

Pw124332 View Pathway
drug action

Troleandomycin Action Pathway (New)

Bacteria
Troleandomycin is a macrolide antibiotic used for the treatment of bacterial infections of the upper and lower respiratory tract such as tonsilitis, bronchitis, sinusitis and pneumonia. Troleandomycin targets the protein synthesis machinery in the bacterial cytoplasm to inhibit protein synthesis and prevent bacterial growth. Troleandomycin enters through the bacterial cell membrane through multidrug resistant protein 1 and binds to the bacterial ribosome. The bacterial ribosome consists of two subunits: the 50s and the 30s subunit. Troleandomycin binds to the 50s subunit and prevents translocation of the tRNA along the A, P and E sites of the ribosome. Translocation of amino acids from the acceptor site (A site) to the donor site (P site) is prevented and as a result, protein synthesis is halted. The bacterial cells are unable to generate proteins necessary for growth and duplication, therefore, growth of the bacteria is inhibited. Side effects from taking troleandomycin may include abdominal cramping and discomfort, nausea and vomiting, diarrhea, dizziness, fatigue, headache, vaginal yeast infection and allergic reactions including urticaria, skin rashes and anaphylaxis.

PW000707

Pw000707 View Pathway
drug action

Troleandomycin Action Pathway

Homo sapiens
Troleandomycin, sold as Triocetin and Tekmisin, is a macrolide antibiotic drug. It is similar to erythromycin, the first macrolide discovered, as well as azithromycin and clarithromycin, which were formed from chemically modified erythromycin. As with other macrolides, troleandomycin binds to the bacterial ribosome, preventing ribosomal translation from occurring, as well as preventing amino acids from being added to the protein during protein biosynthesis. This prevents the bacteria from being able to produce potentially vital proteins, and means that the bacteria will likely die. Troleandomycin may inhibit some Cytochrome P450 enzymes, leading to averse effects to other drugs. Troleandomycin is used to treat pneumonia and streptococcal infection, but it is not yet FDA approved and is only currently used in Turkey.

PW146603

Pw146603 View Pathway
drug action

Troleandomycin Drug Metabolism Action Pathway

Homo sapiens

PW176501

Pw176501 View Pathway
metabolic

Troleandomycin Predicted Metabolism Pathway

Homo sapiens
Metabolites of Troleandomycin are predicted with biotransformer.

PW146640

Pw146640 View Pathway
drug action

Tromantadine Drug Metabolism Action Pathway

Homo sapiens